Development Programs

Kronos Bio is currently advancing two preclinical programs built upon hits identified from the SMM platform and intends to pursue additional discovery efforts against a range of well-validated, historically challenging targets in oncology.

MYC

The MYC family of transcription factors are master regulators of cell proliferation and differentiation, and MYC expression is dysregulated in a large proportion of human cancers. Kronos is developing a series of compounds which act through a novel mechanism to suppress MYC-driven transcription. Early lead compounds have demonstrated activity in multiple MYC-driven cancer models, and Kronos Bio is currently pursuing lead optimization efforts.

AR

The Androgen Receptor (AR) is a primary driver of disease progression in prostate cancer. While multiple approved therapies suppress AR activity by targeting the ligand-binding domain (LBD), mutant splice variants lacking the AR-LBD emerge in hormone-refractory patients, and these patients have limited options. Kronos is progressing multiple hit series which target AR through mechanisms other than AR-LBD, and have been shown to reduce cell growth and AR expression in treatment-resistant cell lines.

Discovery Hit Validation Lead Optimization
MYC
AR
Undisclosed